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Abstract
Background: Pneumonia is a costly and deadly respiratory disease that afflicts millions every
year. Advances in pneumonia care require significant research investment and collaboration
among pneumonia investigators. Despite the importance of data sharing for clinical research
it remains difficult to share datasets with old and new investigators. We present CAPOCloud, a
web-based pneumonia research platform intended to facilitate data sharing and make data more
accessible to new investigators.
Methods: We establish the first two use cases for CAPOCloud to be the automatic subsetting
and constraining of the CAPO database and the automatic summarization of the database in
aggregate. We use the REDCap data capture software and the R programming language to
facilitate these use cases.
Results: CAPOCloud allows CAPO investigators to access the CAPO clinical database and ex-
plore subsets of the data including demographics, comorbidities, and geographic regions. It also
allows them to summarize these subsets or the entire CAPO database in aggregate while pre-
serving privacy restrictions.
Discussion: CAPOCloud demonstrates the viability of a research platform combining data cap-
ture, data quality, hypothesis generation, data exploration, and data sharing in one interface.
Future use cases for the software include automated univariate hypothesis testing, automated
bivariate hypothesis testing, and principal component analysis.
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1 Introduction
Of all infectious diseases, community-acquired pneumonia (CAP)
continues to be one of the most common causes of morbidity for
adults in the world.1 Improving patient outcomes is facilitated by
the generation of new knowledge through clinical research and
quality improvement activities. One of the largest CAP studies is
The Community Acquired Pneumonia Organization (CAPO), orig-
inally developed in 1999 to facilitate collaborative international
research on CAP2. CAPO currently includes investigators from
over 30 countries and 130 healthcare facilities, and the CAPO
database houses data for nearly 20,000 hospitalized patients with
CAP.
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The CAPO database uses the Research Electronic Data Capture
software or REDCap. REDCap is a clinical data management soft-
ware that is accessible online through a secure portal. CAPO
members access the database with a unique username and pass-
word in order to enter data. The database and CAPO web portal
are maintained by the CAPO support group and any pneumonia
investigator may contact the group for the creation of a free ac-
count.3
The primary benefit of this type of shared collaborative database
is the large number of case records it makes available to re-
searchers. Since 2003 the NIH has maintained an official policy
regarding data sharing which highlights the importance of collab-
oration to research.4 This policy emphasizes the importance of
data sharing to the translation of research into practice and re-
quires that NIH funded studies include a data sharing plan that
makes available the timely release and sharing of data. The in-
creasing availability of the internet has provided a greater capa-
bility to share data among researchers, but successful dissemina-
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tion is still challenging for many reasons including differences in
data formats, institutional intellectual property restrictions, and
cost for de-identifying data.5,6 Since its creation, CAPO investi-
gators have published many studies based on data contributed
by CAPO members7–35 and each of these studies required careful
analysis of data, as well as interpretation of results.
1.1 The Problem
Despite the utility that the CAPO system makes available to inves-
tigators, there are several challenges that need to be overcome.
One of the primary problems is that investigators need to contact
the CAPO support group to determine if a study population or
study variable of interest is available in the CAPO database. Once
the population and variables are identified, the data must be ana-
lyzed appropriately. Currently, analyses are conducted through
two means: 1) The CAPO support group at the University of
Louisville provides a raw dataset to investigators for analysis, or
2) the CAPO support group analyzes data and reports back to the
investigator. Both of these approaches are cumbersome and time-
consuming, typically necessitating several meetings to explain the
data, methods, and results.
These issues are not unique to the CAPO database. Presently the
only way to determine if a large pneumonia database might be
appropriate for secondary analysis is to contact the original in-
vestigators and request the data. Even if the original investigators
are willing to collaborate, there may be added costs of data de-
identification and intellectual property agreements between insti-
tutions. These will add weeks and months to the time needed to
form the first hypothesis for a secondary analysis.
1.2 Objective
The objective of this project was to develop and implement a
cloud-based, interactive analytic and data visualization research
platform with the following aims: 1) Promote new research 2)
facilitate education of new researchers 3) enable the exploration
of research ideas not envisioned by the initial protocol 4) make
possible the testing of new or alternative hypothesis and 5) facil-
itate exploratory data analysis of the original study database. We
believe that using data analytics and visualization techniques can
improve secondary data analysis not only for the field of pneumo-
nia but also for clinical research in general.
2 Methods
Table 1 summarizes many of the terms used in the design and
development of software for assisting with data analysis.
2.1 Use Cases
When designing software, use cases are used to describe the pur-
pose that software affords to its users. Use cases are described
from the perspective of a typical user of the software. Once use
cases are established, software features are created that will af-
ford and support all of the necessary use cases. In the case of
CAPO-cloud, we focus on two primary use cases: 1) A CAPO In-
vestigator wants to constrain, or subset, the CAPO database and
Table 1 Glossary
Key Terms Description
aggregate data combined from several measurements
API application programmer interface - flexible
software tools for modifying program func-
tionality
checkbox An on-screen graphical element showing a
check when clicked
open source a software licensing model that allows for
no cost redistribution of software and edit-
ing of the program
proprietary a software licensing model that does not al-
low editing of the program
server a computer program that provides data to
other computers on a network
subset to reduce the size of a dataset by excluding
records
use case a desired activity a user wishes to perform
2) A CAPO investigator wants to summarize or describe the CAPO
database in aggregate.
Every feature of the app will be made to address a primary use
case. Addressing the first use case of subsetting the database, re-
quires a feature that allows selecting features of the database such
as demographics. These selections effectively exclude portions of
the CAPO database that do not meet the inclusion criteria of a
research question and is usually done in software by means of a
checkbox. After subsetting the database, an additional feature is
needed to provide summarization of the subset. This feature can
be added by performing calculations and presenting results in a
tabular or graphical format.
To satisfy these use cases, we integrate three open source software
projects: 1) Research Electronic Data Capture (REDCap)36, 2)
The R Programming Language37, and 3) R-Studio/Shiny38.
2.2 REDCap
REDCap is an electronic data capture software that is developed
and maintained by Vanderbilt University. It is web-based software
that can be obtained for eligible organizations at no cost. The
CAPO REDCap database is housed on a secure web server and
comprises multiple data collection forms. REDCap has applica-
tion programmer interface (API) functionality, allowing REDCap
to communicate with a variety of other software and program-
ming languages.
2.3 R
R is a statistical programming language based around S39. R
is open source and free, allowing contributors to write software
packages and contribute to software repositories such as CRAN40,
GitHub41, and BIOConductor42.
2.4 Shiny
Shiny is an R software package created by RStudio43 that allows
programmers to build interactive applications that allow for the
visualization and sharing of data. As with web applications, a
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Shiny application is a web page that accepts inputs from users
via on-screen controls, puts the user inputs into R running on a
server or local computer, and then outputs results back to the web
page, updating or generating the information displayed. Shiny
applications are usually composed of two key units of code: a
script for the functions run by the server and a script for the user
interface.
3 Results
3.1 Integration
Although REDCap does not use R, the REDCap API allows it to
work in conjunction with many modern programming languages
including R, Python43, PHP44, and Perl. Through the API, a soft-
ware developer can create a REDCap "plug-in" or a feature that is
added directly to the REDCap software to be used through its na-
tive interface. The REDCap plug-in runs on the same web server
as the REDCap instance, and connects to the Shiny server which
can be running on the same hardware or on a remote system,
depending on performance and memory requirements. Figure 1
depicts the CAPO-Cloud plug-in for REDCap.
3.2 CAPO-Cloud
After logging in to the CAPO REDCap instance, investigators can
navigate to the CAPO-Cloud plug-in by clicking the CAPO-Cloud
link on the sidebar. This will take them to the CAPO-Cloud About
page, which offers a brief description of the CAPO study and a
patient characteristics table for the whole dataset (see Figure 2).
The next tab, Subset Data, provides the subset selection feature
for the CAPO dataset. Currently, investigators can subset based
on date of admission, sex of patient, age of patient, patient his-
tory of comorbidities, and region. The subsets made on this page
will carry over to all subsequent pages, allowing investigators to
get a unique snapshot of the database from a perspective that
meets their research needs. Figure 3 shows the total number of
male patients aged 85 and over admitted between 2000-04-17
and 2016-11-03 with a history of COPD in the United State and
Canada.
The third tab, Descriptive Statistics, shown in Figure 4 allows in-
vestigators to look at summary statistics in more detail. Statistics
are accompanied by tables and graphs such as histograms and bar
charts. This tab is separated into multiple sections, allowing in-
vestigators to look at patient history and demographics, physical
exam values, laboratory values, severity of disease markers, and
outcomes such as length of stay or in-hospital mortality.
3.3 Security and Privacy
The CAPO database is not completely de-identified, but the sum-
mary statistics provided by CAPO-cloud effectively mask pro-
tected health information. Access is only available upon request-
ing a CAPO REDCap account, and all access is tracked using RED-
Cap’s audit trail.
Fig. 1 CAPO-Cloud architecture. Using the REDCap API to connect to
R, CAPO-Cloud makes use of statistical functions using R-base (core R
programming language) and applies them to data stored in REDCap.
These functions and results are then displayed to the user, via the
shiny-server web interface.
4 Discussion
In this study, we developed and implemented a new cloud-
based interactive analytic and data visualization research plat-
form, CAPO-Cloud, to facilitate hypothesis generation and sec-
ondary data analysis of the CAPO international database. The
platform allows investigators to start secondary data analysis in
an interactive way that is less time consuming and more acces-
sible than what was previously available. It supports real-time
subsetting and summarizing of the CAPO clinical database.
Increased focus on research has improved the availability of soft-
ware which supports exploratory analysis. Proprietary software
like Microsoft Excel and Tableau can load a data file exported
from REDCap or other data collection systems and display graphs
and tables similar to what is seen in CAPO-Cloud. Companies
like IBM and Google have also invested heavily in providing open
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Fig. 2 The About page for the CAPO-Cloud plug-in. The standard REDCap command options are seen on the left side, with choices for determining
project setup. Under the project title, the interface for CAPO-Cloud is shown, and lists a patient characteristics table for the complete dataset.
Fig. 3 The Subset Data page
Fig. 4 The Descriptive Statistics page
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and available means to visualize data with their products Many
Eyes45 and Fusion Tables46. For investigators who are skilled
with these tools, they are often sufficient to provide a general
overview of a clinical dataset.
Excel provides a convenient way to interact with and edit data,
and although it is proprietary software, it is not prohibitively ex-
pensive, and available to most students and employees at a re-
duced price or for free. However, Excel has limits when it comes
to the size of a dataset that can be managed, and to performing
any specialized statistics requires familiarity with Excel’s formula
language.
Tableau supports a point and click interface, allowing investiga-
tors to drag variables names to create charts and other data visu-
alizations based on their selections. To get meaningful visualiza-
tions, a Tableau user must know what type of data is associated
with each variable name. Most investigators, and especially in-
vestigators new to clinical research and statistics, could not dis-
cern this from the raw data alone, and so many datasets will have
an accompanying data specification or data dictionary describing
this information. This dictionary provides the data type, units,
validity ranges, and any other relevant information about a vari-
able. Even having access to this dictionary does not make initial
data exploration steps approachable for a new investigator, as the
amount of options available to new users when first opening the
dataset in Tableau can be overwhelming.
None of this software achieves an integration with the same data
collection and quality framework on which it was collected, and
this is a key advantage of the CAPO-Cloud. Having the analy-
sis and visualization tools ensures that investigators will only see
capabilities that apply to the CAPO pneumonia dataset. This is
crucial in making investigation approachable and reproducible.
4.1 Strengths
All software used for this project is available at no cost to eligible
organizations, and anyone with access to REDCap can create a
similar platform tailored to their studies. Any investigator inter-
ested in pneumonia data can become a member of CAPO and be
granted access to the CAPO clinical database and CAPO-Cloud.
The platform provides visualization that aids clinicians and re-
searchers without a strong statistical background in the genera-
tion of new ideas for research. This allows researchers who were
not part of the original study to initiate secondary data analyses
of the clinical database on their own, allowing the CAPO support
unit to focus on sophisticated, high-level analysis developed from
investigators’ hypotheses.
4.2 Limitations
Currently, this platform can only be applied to one database (the
CAPO database). Applying to other REDCap projects would re-
quire some modification from a programmer experienced in R and
Shiny. REDCap is not open source and is only available upon re-
quest from the REDCap consortium. REDCap can only be licensed
for use that is considered not-for-profit. This includes academic,
government and non-profit organizations, but not industry or pri-
vate enterprise.
4.3 Future research
CAPO-Cloud supports use cases for the exploratory browsing and
descriptive statistics of the CAPO database for CAPO investigators.
In Table 2 we list several use cases and the features to support
them that we anticipate to be useful to CAPO investigators in the
future.
Table 2
Use case
Investigators wish to:
Feature(s) to be added
perform hypothesis testing between two
variables.
Inferential Statistics (bivariate) Tab:
Chi-square tests, two population t-tests,
simple linear regression
perform multivariate hypothesis testing, al-
lowing for adjustment of other variables.
Inferential Statistics (multiple regression)
Tab:
Multiple regression, logistic regression,
parametric survival analysis
identify outliers and perform basic data
quality monitoring.
Data Quality Improvements:
Identification of outliers, tools to address
data quality fixes
get more meaningful interpretations for sta-
tistical tests performed.
Educational component:
Explain tests, explain what results mean,
provide meaningful context for statistical
perform more complicated analyses or se-
lect variables for analysis based on data-
driven methods.
Advanced Inferential tab:
Principal component analysis, genetic algo-
rithms for variable selection, machine learn-
ing processes for model selection
use other pneumonia clinical databases
in conjunction with CAPO international
database.
Expand application to be usable for other
pneumonia databases
use other clinical databases for other dis-
eases.
Expand application to be usable for any
clinical database
Many of these functions are in use by the CAPO coordinating cen-
ter as standalone R programs, and only need adjustment for pre-
sentation on a web page through Shiny.
In order to understand the impact that CAPO-Cloud has on in-
vestigators, it will be important to track CAPO-Cloud usage and
follow up regularly with investigators using it, to determine which
features are the most useful. Features that facilitate studies lead-
ing to publication will have the highest priority.
4.4 Conclusions
In conclusion, we have presented our project CAPO-Cloud, a
REDCap plug-in that aims to create a basic structure for a cloud-
based research program facilitating collaborative research and
data sharing at the international level. We believe that tools like
these will greatly enhance the ability of non-statisticians to per-
form preliminary investigations into important new clinical re-
search questions.
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